^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
iNeo-Vac-P01
i
Other names: iNeo-Vac-P01
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Hangzhou Neoantigen Therap
Drug class:
Immunostimulant
Related drugs:
3years
A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment. (PubMed, Front Immunol)
As one of the earliest studies that addressed an issue in treating pancreatic cancer with personalized vaccines, it has been demonstrated that iNeo-Vac-P01, a personalized neoantigen-based peptide vaccine, could improve the currently limited clinical efficacy of pancreatic cancer. ClinicalTrials.gov, identifier (NCT03645148).Registered August 24, 2018 - Retrospectively registered.
Clinical • Retrospective data • Journal • Tumor Mutational Burden
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
|
TMB-L
|
iNeo-Vac-P01
over3years
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors (clinicaltrials.gov)
P1, N=30, Recruiting, Sir Run Run Shaw Hospital
Clinical • New P1 trial • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
|
iNeo-Vac-P01
Share via
